Latest News
ALOFT Study

ALOFT Study Shows Excellent Long-Term Visual Benefit

July 2022

A study recently published in Ophthalmology Retina looked at more than 2,000 ForeseeHome patients from five clinics over a 10-year period. The results demonstrated excellent long-term vision in a real-world setting after wet AMD conversion.

Home-based monitoring programs promise to extend care for diseases with acute onset and limit physician time for patient disease and compliance education. However, there is limited long-term real-world data that shows the efficacy of these programs. The Analysis of the Long-term Visual Outcomes of ForeseeHome Remote Telemonitoring (ALOFT) study1 was designed to understand long-term, real-world visual outcomes and compliance for patients being monitored by the Notal Vision Monitoring Center and performing ForeseeHome preferential hyperacuity perimetry (PHP) tests, as prescribed by their physician.

The ALOFT study found that the average visual acuity at wet AMD conversion was 20/39, compared to 20/83 in the American Academy of Ophthalmology's IRIS® Registry (non-ForeseeHome users).2 More importantly, 82% of patients maintained functional vision (20/40 or better) with treatment for years after conversion. This is in stark contrast to 20/80 or worse using standard of care alone.3

As discussed in last month’s newsletter, real-world compliance to frequent testing was also excellent. The ALOFT study reported that ForeseeHome patients tested an average of 5.2 times per week over a period of 10 years. The AREDS2-HOME study established that patients need to test at least two times a week for the ForeseeHome device to be efficacious.2 Medicare also requires eight tests per months for patient reimbursement of the monitoring service.

The Notal Vision Monitoring Center, along with the home-based ForeseeHome device and the doctor’s reinforcement, provide a remote monitoring service model that demonstrates significantly better visual outcomes for patients using the ForeseeHome monitoring program, compared to the standard of care that relies on office visits and patient self-reported symptoms alone.

Read the ALOFT Study

Click Here

References

  1. Mathai M., Reddy S., Elman M.J., Garfinkel R.A., Ladd B., Wagner A., Sanborn G.E., Jacobs J., Busquets M., Chew E.Y. on behalf of the ALOFT study group. Analysis of the Long-term visual Outcomes of ForeseeHome Remote Telemonitoring - The ALOFT study. Ophthalmology Retina (2022), doi: https://doi.org/10.1016/j.oret.2022.04.016.
  2. Ho AC, Kleinman DM, Lum FC, Heier JS, Lindstrom RL, Orr SC, Chang GC, Smith EL, Pollack JS. Baseline Visual Acuity at Wet AMD Diagnosis Predicts Long-Term Vision Outcomes: An Analysis of the IRIS Registry. Ophthalmic Surg Lasers Imaging Retina. 2020 Nov 1;51(11):633-639. doi: https://doi.org/10.3928/23258160-20201104-05.
  3. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, Toth CA, Ferris FL 3rd, Fine SL. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016 Aug;123(8):1751-1761. doi: https://doi.org/10.1016/j.ophtha.2016.03.045.

Related News

View Latest News
View Latest News